Cryoballoon Ablation: GIE | July 2026

Introduction:

Cryoballoon ablation (CbA) is an emerging endoscopic ablative technology that delivers focal cryotherapy without the need for a decompression tube, making the procedure simpler and more efficient than traditional cryospray systems. Initially developed for Barrett's esophagus (BE), its applications are rapidly expanding to other gastrointestinal disorders. This "Top Tips" review provides practical guidance for therapeutic endoscopists on optimizing CbA and highlights its evolving role across the GI tract.

Why was this review needed?

Cryoballoon ablation is increasingly used, but practical procedural guidance remains limited.

Compared with conventional cryospray, CbA simplifies the procedure by eliminating the need for gastric decompression.

CbA offers an alternative for patients who fail or are unsuitable for radiofrequency ablation (RFA).

New indications for CbA continue to emerge beyond Barrett's esophagus.

Standardized technical tips may improve efficacy while minimizing complications such as esophageal strictures.

Key Takeaways:

Barrett's esophagus remains the primary indication, with CbA demonstrating excellent efficacy for dysplasia and residual Barrett's mucosa.

CbA is particularly valuable for RFA-refractory Barrett's esophagus, providing an effective salvage treatment option.

Compared with radiofrequency ablation (RFA), CbA is associated with less post-procedural pain, potentially improving patient comfort.

Although esophageal stricture rates are comparable to RFA, careful technique and appropriate treatment spacing can minimize this risk.

CbA can also be used for esophageal tumor palliation, although severe malignant strictures may currently limit balloon positioning.

Emerging applications include treatment of gastric antral vascular ectasia (GAVE), chronic radiation proctopathy, and selected small duodenal adenomas.

One practical advantage is that no dedicated capital equipment purchase is required, lowering barriers to adoption for endoscopy units already performing therapeutic procedures.

Ongoing device refinements, including balloons specifically designed for malignant strictures, are expected to further expand clinical applications.

Clinical Impact:

Cryoballoon ablation is rapidly becoming an important addition to the therapeutic endoscopist's armamentarium. Its ease of use, favourable patient tolerance, and versatility make it particularly attractive for the management of Barrett's oesophagus, especially after failed RFA. As clinical experience grows and newer devices become available, CbA is likely to play an expanding role in treating selected benign and malignant gastrointestinal disorders.

Bottom Line:

Cryoballoon ablation is a simple, effective, and well-tolerated endoscopic ablation technique with established value in Barrett's oesophagus and growing applications in oesophagal tumours, GAVE, radiation proctopathy, and selected duodenal adenomas. Its procedural simplicity and expanding indications are expected to accelerate adoption in therapeutic GI endoscopy.